Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide (B/F/TAF) from a boosted protease inhibitor-based regimen

被引：0
|
作者：
Rockstroh, J. [1 ]
Molina, J. M. [2 ]
Post, F. [3 ]
Fox, J. [4 ]
Koenig, E. [5 ]
Daar, E. S. [6 ]
Ruane, P. [7 ]
Crofoot, G. [8 ]
Oguchi, G. [9 ]
Creticos, C. [10 ]
Liu, A. [11 ]
Andreatta, K. [11 ]
Graham, H. [11 ]
Brainard, D. [11 ]
Martin, H. [11 ]
机构：
[1] Univ Hosp Bonn, Bonn, Germany
[2] Hop St Louis, Paris, France
[3] Kings Coll Hosp NHS Fdn Trust, London, England
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] Inst Dominicano Estudios Virol IDEV, Santo Domingo, Dominican Rep
[6] Harbor UCLA Med Ctr, Lundquist Inst, Torrance, CA 90509 USA
[7] Ruane Clin Res Grp Inc, Los Angeles, CA USA
[8] Crofoot Res Ctr, Houston, TX USA
[9] Midland Florida Clin Res Ctr, Deland, FL USA
[10] Howard Brown Hlth Ctr, Chicago, IL USA
[11] Gilead Sci Inc, Foster City, CA USA
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
O005
引用
收藏
页码：5 / 5
页数：1
相关论文
共 50 条
  • [1] Long-term follow-up after a switch to bictegravir, emtricitabine, tenofovir alafenamide, from a boosted protease inhibitor-based regimen
    Rockstroh, J.
    Molina, J.
    Post, F.
    Fox, J.
    Koenig, E.
    Daar, E.
    DeJesus, E.
    Ruane, P.
    Crofoot, G.
    Oguchi, G.
    Creticos, C.
    Liu, A.
    Andreatta, K.
    Graham, H.
    Brainard, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 41 - 42
  • [2] Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips
    Andreatta, K.
    Chang, S.
    Delaney, M.
    Willkom, M.
    Martin, R.
    Graham, H.
    Martin, H.
    White, K. L.
    HIV MEDICINE, 2021, 22 : 72 - 73
  • [3] Modelling the long-term clinical outcomes of the novel single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the UK
    Hearmon, N.
    Matin, N.
    Painter, C.
    Robinson, C.
    Eddowes, L.
    Kearns, S.
    Jandu, S.
    Wild, L.
    HIV MEDICINE, 2019, 20 : 21 - 21
  • [4] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J.
    Stellbrink, H-J
    DeJesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D.
    Collins, S.
    Martin, H.
    HIV MEDICINE, 2020, 21 : 18 - 18
  • [5] Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults
    Orkin, C.
    Sax, P. E.
    Arribas, J.
    Gupta, S.
    Martorell, C.
    Stephens, J. L.
    Stellbrink, H-J
    Dejesus, E.
    Maggiolo, F.
    Huang, H.
    Acosta, R.
    Brainard, D. M.
    Collins, S. E.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 94 - 95
  • [6] Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV-infected individuals: evidence for long-term efficacy
    Truong, David
    Yi, Shana
    Wiesmann, Christina
    Conway, Brian
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 181 - 181
  • [7] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [8] Switching from a second-line ritonavir-boosted protease inhibitor-based regimen to bictegravir/emtricitabine/ tenofovir alafenamide: results of a randomized clinical trial
    Pierre, S.
    Marc, J. B.
    Homeus, F.
    Bernadin, G. R.
    Trevisi, L.
    Jean, E.
    Dumont, E.
    Sundaresan, S.
    Rivera, V.
    Israelski, D.
    Collins, S. E.
    Pape, J. W.
    Liautaud, B.
    Severe, P.
    Sax, P. E.
    Koenig, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 26 - 26
  • [9] Metabolic effects of switching to tenofovir alafenamide/emtricitabine/bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens: METABIC study
    Busca, C.
    Ortega, D.
    Martin-Carbonero, L.
    Mican, R.
    Ramos, L.
    Valencia, M.
    Montejano, R.
    Montes, M.
    Diaz-Almiron, M.
    Delgado, A.
    Bernardino, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 150 - 151
  • [10] Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in combination with boosted darunavir (DRV) in treatment experienced patients with HIV
    Hill, L.
    Momper, J.
    Abulhosn, K.
    Ballard, C.
    Young, M.
    HIV MEDICINE, 2019, 20 : 81 - 81
12345